On July 23, 2019, the FDA announced that it expects to issue an update on the agency’s progress formulating a regulatory framework for products containing cannabidiol (CBD) in the early fall. This announcement came following the FDA’s warning letter to the company Curaleaf for selling CBD products online without approval. The FDA is planning to create a pathway for cannabis-derived products, based on a stepwise science-based approach. FDA Acting Commissioner Ned Sharpless indicated that the FDA will continue to closely watch the CBD marketplace for instances of misbranding. Unapproved products advertising potentially false health claims can have serious public health implications. This FDA announcement indicates that progress is being made towards the lawful production and sale of cannabis-based products, but in the meantime, the FDA will continue issuing warning letters to companies producing unapproved new CBD related drugs. Aimed Alliance hopes that this framework will help reduce consumer confusion and risks that come with unregulated CBD products.